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Due to the lack of an adequate conventional therapy 
against  lower  limb  ischemia,  gene  transfer  for  thera-
peutic  angiogenesis  is  seen  as  an  attractive  alterna-
tive.  However,  the  possibility  of  side  effects,  due  to 
the expression of large amounts of angiogenic factors, 
justifies  the  design  of  devices  that  express  synergistic 
  molecules in low controlled doses. We have developed 
an internal ribosome entry site (IRES)–based bicistronic 
vector expressing two angiogenic molecules, fibroblast 
growth  factor  2  (FGF2),  and  Cyr61.  Through  elec-
trotransfer  into  the  ApoE−/−  mice  hindlimb  ischemic 
muscle model, we show that the IRES-based vector gives 
more stable expression than either monocistronic plas-
mid. Furthermore, laser Doppler analysis, arteriography, 
and immuno  chemistry clearly show that the bicistronic 
vector promotes a more abundant and functional revas-
cularization than the monocistronic vectors, despite the 
fact that the bicistronic system produces 5–10 times less 
of each angiogenic molecule. Furthermore, although the 
monocistronic Cyr61 vector accelerates B16 melanoma 
growth in mice, the bicistronic vector is devoid of such 
side effects. Our results show an active cooperation of 
FGF2 and Cyr61 in therapeutic angiogenesis of hindlimb 
ischemia, and validate the use of IRES-based bicistronic 
vectors for the coexpression of controlled low doses of 
therapeutic molecules, providing perspectives for a safer 
gene therapy of lower limb ischemia.
Received 22 April 2009; accepted 13 August 2009; published online  
8 September 2009. doi:10.1038/mt.2009.211
IntroductIon
Lower  limb  arterial  disease  is  a  pathology  with  a  prevalence 
of about 12% (ref. 1). Critical limb ischemia, which has a high 
prevalence in diabetic patients, affects about 500 new individuals/
million/year in the United States and Europe. Even with medi-
cal treatments, such as arterial angioplasty and arterial bypass, 
only 25% of limbs can be salvaged. More than 50% of patients die 
within 5 years, despite amputation of necrosed limbs, and their 
quality of life is deplorable.
In  this  context,  therapeutic  angiogenesis,  which  aims  to 
restore tissue perfusion in response to angiogenic growth factors, 
represents a promising alternative. The principle of therapeutic 
angiogenesis is to administer angiogenic regulators that stimulate 
the establishment of a stable, functional vascular network. Several 
major  angiogenic  growth  factors,  such  as  vascular  angiogenic 
growth factor, fibroblast growth factor 1 (FGF1), and fibroblast 
growth factor 2 (FGF2), as well as other angiogenic   molecules have 
been assayed in several preclinical and clinical studies employing 
protein or gene therapy.2,3 Although protein therapy is inconve-
nient due to the short half-life of therapeutic molecules, gene 
therapy permits the sustained production of angiogenic factors 
and results in prolonged exposure to the therapeutic molecules. 
Plasmid-based systems are presently being used in clinical trials 
of lower limb ischemia.4–6
The current clinical trials are based on the use of a single 
angiogenic factor, mainly vascular angiogenic growth factor or 
FGF.4,6 However, the formation of a functional vascular network 
is a complex process that requires several angiogenic factors in 
order to obtain capillary sprouting as well as induce the growth 
and remodeling of collateral arteries.7
Co-injecting two different therapeutic expression vectors does 
not ensure that both products will be expressed with the expected 
ratio, as various events can lead to preferential silencing or removal 
of one vector.8 Combined gene therapy for therapeutic angiogene-
sis thus necessitates the development of an adequate gene transfer 
system that allows stable coexpression of both molecules. In this 
context, the use of internal ribosome entry sites (IRESs) provides 
an attractive approach to coexpress combinations of molecules. 
IRESs, RNA structural elements present in the 5′ untranslated 
region of several mRNAs, permit an internal recruitment of the 
translational  machinery.  They  can  be  used  as  biotechnologi-
cal tools to drive expression of additional genes encoded within 
a single mRNA.9 Thus, IRESs permit the design of expression 
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cassette coding for combinations of therapeutic molecules on the 
same transcription unit. Furthermore, IRESs may be tissue and/or 
context specific. In particular, we have previously shown that the 
FGF1 IRES is very active in skeletal muscle and capable of being 
used in gene transfer vectors targeted to ischemic limbs.8,10
In the present study, we have designed an IRES-based, bicis-
tronic vector in order to optimize therapeutic angiogenesis in the 
mouse ApoE−/− model of hindlimb ischemia.11 FGF2 and Cyr61 
were chosen as angiogenic molecules, as both have been reported 
as therapeutic candidates.3,12 Cyr61 (also known as CCN1) belongs 
to the CCN (cyr61, ctgf, and nov) family, matri-cellular regulatory 
factors involved in internal and external cell signaling. Recently 
characterized as an angiogenic factor, Cyr61 is a heparin-binding, 
extracellular matrix–associated protein that mediates endothelial 
cell adhesion and migration by binding to integrin α2β3 (ref. 13). 
Cyr61 plays a role in both physiological and pathological angio-
genesis.13 In addition, Cyr61 has been described for its ability to 
enhance FGF2-induced DNA synthesis in endothelial cells.13–15 
We  compared  mono-  and  bicistronic  vectors  expressing  FGF2 
and/or Cyr61 after intramuscular administration of naked DNA. 
Their efficacy was evaluated in an ischemia leg model and their 
safety was tested in a heterotopic tumor model.
results
Ires-based bicistronic vectors generate 
lower amounts of FGF2 and cyr61 than 
monocistronic vectors
In order to test the potential synergism of FGF2 and Cyr61 in 
the promotion of therapeutic angiogenesis, an IRES-based bicis-
tronic vector was generated. We used the FGF1 IRES, previ-
ously shown to be the most efficient for gene transfer in skeletal 
muscle.8,10 The complementary DNAs coding Cyr61 or FGF2 
were  subcloned  into  monocistronic  and  bicistronic  vectors 
(Figure 1a;  pC-FGFiCyr,  pC-Cyr,  and  pC-FGF,  respectively). 
Bicistronic  control  vectors  were  also  constructed:  pC-FGFiL 
codes for FGF2 and firefly luciferase (Luc F), whereas pC-RiCyr 
codes for Renilla luciferase (Luc R) and Cyr61. These two vec-
tors, which express a single angiogenic molecule in the bicis-
tronic context, permit the evaluation of the effects of FGF2 or 
Cyr expressed individually but at similar doses to those obtained 
with the FGF-Cyr vector pC-FGFiCyr. Indeed, monocistronic 
vectors are expected to generate higher amounts of molecules of 
interest than their bicistronic counterparts.8 The bicistronic vec-
tor pC-RiL serves as a negative control that produces Luc R and 
Luc F. Efficient expression of FGF2 and/or Cyr61 by the different 
plasmids was checked by transient transfection of COS-7 cells. 
As expected, the bicistronic vectors expressed lower amounts 
of  both  angiogenic  factors  than  the  monocistronic  vectors 
(Supplementary Figure S1).
The  different  plasmids  were  electrotransferred  in  tibialis 
anterior muscle of ApoE−/− mice with the expression of FGF2 
and Cyr61 followed by western blot analysis. A semiquantita-
tive analysis of vector expression was performed by serial dilu-
tion of the samples (Figure 1b,c). For both FGF2 and Cyr61, 
the monocistronic vectors were highly expressed, but decreased 
30-fold between day 7 and day 21. In contrast, bicistronic vec-
tor expression decreased only three- to fivefold during the same 
time period. Because the two vectors are expressed with a similar 
efficiency at day 21, we can deduce that day 7 bicistronic expres-
sion is about 5–10 times less efficient than the monocistronic vec-
tor, but that the bicistronic vector delivers more stable expression 
over time.
The different vectors were then electrotransferred into the 
ischemic muscles of mice submitted to surgery (see Materials 
and Methods). Expression of the two angiogenic factors was fol-
lowed between day 7 and day 21 (Supplementary Figure S2a,b). 
The Cyr61/FGF2 detected in the control transfectants (pC-RiL) 
corresponds  to  endogenous  protein.  In  nonoperated  mice, 
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Figure 1  Monocistronic and bicistronic vector construction and expression in mouse tibialis anterior muscle. (a) Schematics of monocistronic 
and bicistronic vectors. The monocistronic plasmids encode either human FGF2 or human Cyr 61 under the control of the cytomegalovirus (CMV) pro-
moter. Bicistronic vectors contain two genes separated by the FGF1 IRES A.24 The first gene is FGF2 or Renilla luciferase (Luc R). The second gene is Cyr 
61 or firefly luciferase (Luc F). These plasmids have the same skeleton as the monocistronic vectors (see Supplementary Materials and Methods). 
(b,c) Semiquantitative analysis of FGF2 and Cyr61 expression. Following electrotransfer in tibialis anterior of monocistronic or bicistronic plasmids pC-
FGF, pC-Cyr, or pC-FGFiCyr (50 µg each), muscle extracts (serial dilution by 1/3, 1/9, and 1/27 for the monocistronic vectors) were analyzed 7, 14, or 
21 days after electrotransfer, by western blot using anti-FGF2 (b) or anti-Cyr61 (c) antibodies (see Supplementary Materials and Methods).2012  www.moleculartherapy.org  vol. 17 no. 12 dec. 2009     
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the monocistronic vectors expressed high levels of angiogenic 
  factors at day 7, with a strong decrease in expression at day 21. In 
contrast, the bicistronic vectors expressed the therapeutic mole-
cules in a less efficient but more stable manner (Supplementary 
Figure S2c,d).
In order to investigate the mechanism that leads to less effi-
cient protein expression with the IRES containing constructs, we 
transfected C2C12 myoblasts with the different vectors. Protein 
expression was higher with the monocistronic than with the bicis-
tronic vectors in C2C12, as observed in muscle (Supplementary 
Figure S3a,b). However, the mRNA amount quantified by reverse 
transcription and quantitative PCR using either FGF2 or Cyr61 
primers,  revealed  similar  amounts  of  mono-  and  bicistronic 
mRNAs, suggesting that their different protein expression results 
from a translational process (Supplementary Figure S3c,d).
FGF2 and cyr61 cooperate to stimulate  
angiogenesis in vitro
Cyr61 has been shown to mediate enhancement of FGF2-induced 
DNA synthesis in human umbilical vein endothelial cells.15 This 
prompted  us  to  evaluate  a  possible  cooperative  effect  of  both 
angiogenic factors on angiogenesis in vitro. Conditioned media, 
obtained  from  293  cells  transfected  by  the  monocistronic  or 
bicistronic vectors containing FGF2, Cyr61 or both, were used 
to treat adult bovine aortic endothelial cells plated on Matrigel 
(Figure 2). Angiogenesis was assessed by quantification of the 
branch points, showing that FGF2 is more angiogenic than Cyr61, 
in vitro (Figure 2a,b). However, conditioned medium from cells 
transfected with the bicistronic vector FGF-Cyr was slightly, but 
significantly more efficient at stimulating angiogenesis than con-
ditioned media containing FGF2 alone, suggesting a cooperation 
of the two angiogenic factors.
the FGF-cyr bicistronic vector generates efficient 
blood perfusion and reduced necrosis and 
inflammation with low doses of angiogenic factors
In order to test the effect of the therapeutic vectors on revascular-
ization of ischemic tissues, we used the hindlimb ischemia model 
described previously.11 Surgery was performed on hypercholester-
olemic ApoE−/− mice, which have been shown to exhibit delayed 
skeletal  muscle  healing  after  hindlimb  ischemia–reperfusion.16 
Naked DNA was electrotransferred just following surgery, and the 
effect of the different vectors on tissue reperfusion was measured 
by laser Doppler imaging (Figure 3a,b). Data showed that the 
monocistronic as well as the bicistronic vectors expressing FGF2 
and/or Cyr61 were able to improve limb reperfusion from day 7 
after treatment, with an optimal effect at day 14 (Figure 3c). The 
effect of the angiogenic vectors decreased at day 21, as a probable 
result of both lower vector expression and natural revasculariza-
tion occurring in mice without treatment.
These data show that coexpression of low doses of FGF2 and 
Cyr61 by the bicistronic vector are able to elicit reperfusion as 
efficiently as the five- to tenfold higher doses produced by the 
monocistronic vectors (Figure 3c,d compare pC-FGFiCyr with 
pC-Cyr and pC-FGF). In order to check the hypothesis of a syn-
ergy  between  the  two  angiogenic  factors,  we  used  the  control 
bicistronic vectors expressing FGF2 or Cyr61 alone at low doses 
(Figure 3e, pC-FGFiL and pC-RiCyr). The efficiency of these con-
structs on reperfusion was less important, suggesting a synergistic 
effect of FGF2 and Cyr61 on revascularization.
The beneficial effect of the angiogenic vectors was also evalu-
ated by determining the degree of ischemia, based on the pres-
ence or absence of necrosis, for each individual (Figure 4, see 
Materials and Methods). Coexpression of FGF2 and Cyr61 by the 
bicistronic vector decreased hindlimb necrosis by 37%, whereas 
necrosis in the untreated controls was at 85% (Figure 4, pC-FG-
FiCyr). The beneficial effect of the bicistronic vector on necrosis 
was similar or superior to that of the monocistronic vectors (48 
and 39% of necrosed tissue for pC-Cyr and pC-FGF, respectively), 
confirming the synergistic effect of FGF2 and Cyr61 coexpressed 
at low doses.
As Cyr61 has been described to promote the inflammation 
response, the presence of macrophages was analyzed 21 days after 
surgery/electrotransfer by immunodetection of CD11b. A large 
number  of  macrophages  were  detected  in  the  muscles  treated 
by  the  control  vector  pC-RiL  indicating  strong  inflammation 
(Figure 4b). The treatment by either of the angiogenic vectors 
generated a decrease in macrophage accumulation, even for pC-
Cyr, which is less anti-inflammatory than pC-FGF. Interestingly, 
the  bicistronic  vector  pC-FGFiCyr  was  the  most  efficient  at 
  accelerating inflammation resolution (Figure 4b).
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Figure 2  effect of cyr61 and FGF2 on endothelial cell tubulogen-
esis  in  vitro. ( a)  Representative  photographs  of  adult  bovine  aortic 
endothelial cells plated on Matrigel-coated wells in the presence of cell-
conditioned media (60 µl), a mix of pC-FGF (30 µl) and pC-Cyr (30 µl) 
conditioned media [called pC-FGF (50%) + pC-Cyr (50%)], and a mix of 
pC-FGF (30 µl) conditioned media and Opti-MEM (30 µl) (called pC-FGF 
50%) after 20 hours. (b) Branch points were quantified. The data shown 
are the mean ± SEM (n = 3 wells per group) (*P < 0.05, **P < 0.01 versus 
control group) of a representative duplicate experiment.Molecular Therapy  vol. 17 no. 12 dec. 2009  2013
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the bicistronic vector enables the synergistic 
effect of FGF2 and cyr61 to act on angiogenesis 
and arteriogenesis in ischemic hindlimb
In  order  to  evaluate  more  precisely  the  effect  of  the  bicis-
tronic  vector  on  angiogenesis  and  arteriogenesis,  ischemic 
hindlimb  revascularization  was  analyzed  by  angiography  and 
immunohistochemistry.
Angiographic  analysis  of  collateral  vessel  development  in 
the ischemic leg was investigated 21 days after surgery/transfec-
tion  (Figure 5a  and  Supplementary Figure S4).  Importantly, 
quantification of the vascular networks demonstrated that the 
angiographic score is significantly higher after treatment with 
bicistronic FGF-Cyr (Figure 5b and Supplementary Figure S4d, 
pC-FGFiCyr) but not with the other vectors. The bicistronic vec-
tor was also the only one to generate a significant increase of ves-
sel length and the number of segments (Figure 5c,d). In addition, 
bicistronic FGF-Cyr generated the best perfusion of the distal 
end of the leg, explained by major arteriogenesis on the thigh 
(Figure 6).
Capillary density and mature vessel formation were analyzed 
by immunohistochemistry using antibodies against CD31, α-SMA, 
or β-dystroglycan to detect endothelial cells, smooth muscle cells, 
and skeletal muscle fibers, respectively (Figure 7). As expected, the 
monocistronic vector expressing FGF2, a strong inducer of capil-
lary vessel formation, had a higher effect than the vector express-
ing Cyr61 (Figure 7b). FGF2 was also more efficient than Cyr61 at 
inducing the formation of mature vessels (Figure 7c). However, the 
bicistronic vector coexpressing FGF2 and Cyr61 was able to increase 
the number of capillaries and mature vessels, related to muscle fibers, 
more efficiently than the monocistronic vector that expresses higher 
levels of FGF2. Similar data were obtained when reporting vessel 
number with respect to the surface area (data not shown).
Taken together, these data show that coexpression of low doses 
of FGF2 and Cyr61, through the bicistronic vector, is significantly 
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Figure 3  effect of angiogenic vector treatment on blood flow recovery in the ischemic hindlimb. (a) Experimental protocol. The days are 
indicated (D1–D21) and the dates of laser Doppler imaging (LDI) are indicated. (b) Representative LDI before surgery and at day 14 after surgery 
for each group. A color scale illustrates blood flow variations from minimal (dark blue) to maximal (red) values. Immediately after unilateral femoral 
artery excision (D0), a marked reduction in blood flow of one hindlimb appears in blue. (c,d) Comparison of treatments by the bicistronic vector pC-
FGFiCyr or by monocistronic vector pC-FGF or pC-Cyr measured by quantification of LDI ratio (ischemic limb/nonischemic limb) in ApoE−/− mice. 
LDI was performed preoperatively, postoperatively, and every week until day 21 postoperatively. (c) Mice were treated by electrotransfer of either 
pC-FGFiCyr, pC-FGF or the control pC-RiL. (d) Mice were treated by either pC-FGFiCyr, pC-Cyr or the control pC-RiL. (e) Comparison of treatments 
with the bicistronic control vectors expressing FGF2 or Cyr alone (pC-FGFiL and pC-RiCyr) or the monocistronic vector pC-FGF. Mice were treated by 
electrotransfer of either pC-FGFiL, or pC-RiCyr, or pC-FGF, or pC-RiL, and LDI was performed as above. The data are the mean ± SEM (n = 7 animals 
per group) (*P < 0.05, **P < 0.01, ***P < 0.001 versus control group). Each experiment was performed in triplicate.2014  www.moleculartherapy.org  vol. 17 no. 12 dec. 2009     
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more efficient than either monocistronic vector on both angiogen-
esis and arteriogenesis leading to ischemic hindlimb reperfusion.
the bicistronic FGF-cyr vector, in contrast to the 
monocistronic vector expressing cyr61 alone, is 
devoid of side effects on tumor growth
An important issue in developing a gene therapy treatment is gener-
ating a therapeutic vector devoid of undesirable side effects. In par-
ticular, FGF2 and Cyr61, as angiogenic factors, may act to enhance 
tumor progression. For that reason, a vector expressing low doses of 
such molecules will be safer with respect to their side effects.
The two monocistronic vectors expressing FGF2 or Cyr61, 
and the bicistronic FGF-Cyr vector were assessed, as well as the 
control vector coding luciferase genes, for a possible effect on the 
development of B16 melanoma (Figure 8). Results clearly showed 
no undesirable effects with the bicistronic vector coexpressing 
FGF2  and  Cyr61,  whereas  the  monocistronic  vector  express-
ing Cyr61 generated a significant increase in tumor volume and 
weight  (Figure  8a,b).  As  the  monocistronic  vector  expressing 
FGF2 did not increase tumor volume or weight, this deleterious 
action appears to be ascribed to high Cyr61 expression.
The effect of vector treatment was also analyzed in the nonis-
chemic legs of the treated mice, revealing no variation of capillary 
number with any of the therapeutic vectors (Figure 8c).
These data indicate that the IRES-based vector, expressing low 
amounts of synergistic FGF2 and Cyr61, is applicable to a safer 
and efficient form of gene therapy for hindlimb ischemia.
dIscussIon
In the present study, we have developed an IRES-based bicistronic 
vector driving coexpression of two angiogenic molecules, FGF2 
and Cyr61. Our data show that FGF2 and Cyr61 have synergistic 
effects on therapeutic angiogenesis, allowing the bicistronic FGF-
Cyr vector to generate the formation of a more abundant and func-
tional vessel network than the monocistronic vectors, despite the 
fact that the FGF-Cyr vector produces lower amounts of the thera-
peutic molecules than the monocistronic vectors producing FGF2 
or Cyr61 alone. Such a feature of the bicistronic vector is pivotal, 
as it does not induce negative side effects such as the acceleration 
of tumor development, observed when Cyr61 is produced in large 
amounts by the monocistronic vector. These data not only validate 
the concept of synergism of angiogenic molecules coexpressed by 
a single gene transfer vector, but also reveal the importance of con-
sidering the dose and the ratio of the angiogenic molecules, and 
not only the efficiency of expression in gene therapy protocols.
The positive effect of synergism between FGF2 and Cyr61 is 
observed for all parameters of the newly formed collateral vessel 
network: size, length, and abundance. Furthermore, the amount of 
capillaries is also significantly increased. Taken together, the data 
show that association of the two molecules generates a more stable 
and functional vascular network. The efficiency of a combined treat-
ment to improve therapeutic revascularization has previously been 
shown by others in ischemic hindlimb models;17–19 however, we 
show here a real synergism between FGF2 and Cyr61, as the bicis-
tronic FGF-Cyr vector generates improved therapeutic angiogenesis 
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Figure 4  clinical ischemia index and inflammation. (a) The mice were observed for gross changes, and we assessed the degree of necrosis based 
on the presence or absence of pressure sores, gangrene, or autoamputation. The data are the mean of percent ± SEM (n = 7 animals per group) (*P < 
0.05, **P < 0.01 versus control group). Experiments were performed in triplicate. (b) Representative photomicrographs of ischemic tibialis anterior 
muscles stained with anti-CD11b allowing the detection of macrophages 21 days after surgery and electrotransfer. Original magnification ×200. 
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and arteriogenesis with significantly lower doses of the angiogenic 
factors. In a previous report, showing the beneficial effects of FGF2 
and platelet-derived growth factor association, the same dosage 
of molecules was administered either alone or   together.17 In other 
studies  using  gene  transfer,  equal  amounts  of  plasmids  encod-
ing  angiopoietin-1  and  vascular  angiogenic  growth  factor  were 
used either alone or together, whereas the authors used a constant 
amount of total plasmid in the most recent study and reported an 
improved reperfusion due to vascular angiogenic growth factor and 
FGF2 association.18,19 The marked difference in the present study 
is that the doses produced by the bicistronic vector are 5–10 times 
lower than that obtained with the monocistronic vectors.
An interesting issue is why the bicistronic vectors produce less 
angiogenic factors than the monocistronic vectors. The lower level 
but more stable expression concerns not only the second cistron 
(IRES-driven), but also the first cistron. Analysis of mRNA levels 
in C2C12 myoblasts suggests that protein expression levels result 
from a translational event rather than from alterations in mRNA 
Arteriography
pC-RiL
pC-FGFiCyr
pC-Cyr
Min Max
pC-FGF
pC-FGFiL
Vascular network
detection
Computer-
generated image
a
0
pC-RiL
pC-FGFiCyr
pC-Cyr
pC-FGF
pC-FGFiL
1
2
3
b
I
n
t
e
n
s
i
t
y
 
(
R
/
L
 
r
a
t
i
o
) **
0
pC-RiL
pC-FGFiCyr
pC-Cyr
pC-FGF
pC-FGFiL
1
2
3
c
L
e
n
g
t
h
 
(
R
/
L
 
r
a
t
i
o
)
**
0
pC-RiL
pC-FGFiCyr
pC-Cyr
pC-FGF
pC-FGFiL
1
2
3
4
5 d
S
e
g
m
e
n
t
 
n
u
m
b
e
r
 
(
R
/
L
 
r
a
t
i
o
)
**
Figure 5  Angiographic analysis of collateral vessel development in the ischemic limb. (a) Representative angiograms of collateral vessel   formation 
in ApoE KO C57Bl/6 mice at day 21 after surgery. The area of interest (red zone) was delineated by the position of the ligature on the femoral artery, 
the knee, the edge of the femur, and external limit of the leg (left column). The image analysis software (Morpho Expert) detected vessel network 
automatically (medium column) and created computer-generated images (right column) for quantification. A color scale illustrates vessel size varia-
tions from thin (dark blue) to large (red) values. (b–d) Quantitative analysis of three criteria: angiographic score (vessel area) (b), total length (c), and 
number of segments (d) of collateral vessel network. These criteria were determined by pixel analysis and expressed as the ratio of the ischemic to 
nonischemic limb (R/L ratio). The data are the mean ± SEM (n = 6 animals per group) (**P < 0.01 versus control group).2016  www.moleculartherapy.org  vol. 17 no. 12 dec. 2009     
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stability.  The  lower  expression  may  be  related  to  translational 
  features of the FGF1 IRES: it has been previously shown by us and 
others that the presence of an IRES can influence translation of 
the first cistron.10,20 The mechanism proposed by Jünemann et al. 
from their study using the encephalomyocarditis virus IRES is 
that whenever the cap-binding complex eIF-4F has been captured 
to a bicistronic mRNA by binding to a picornavirus IRES via its 
eIF-4G moiety, it can be provided in cis to the 5′ end of the mRNA 
and stimulate translation initiation. In contrast, the present study 
shows an inhibitory effect of the IRES on translation of both cis-
trons. We can hypothesize that the IRES could control the recruit-
ment of the bicistronic mRNA into polysomes, a process that might 
be governed by limiting IRES trans-acting factors, resulting in the 
translational control of both cistrons. Lower expression could also 
limit the elimination of the vector by the mouse immune system 
and result in a more stable long-term expression.
The more efficient long-term expression shown here is con-
sistent with our previous data demonstrating that IRESs allow 
expression of a stable ratio of the two molecules of interest.8 Thus, 
prolonged expression and stable ratio represent two factors that 
could favor the establishment of a stable and functional vessel net-
work. In particular, the ratio may be important for maintaining 
the synergistic effect of the angiogenic molecules.
The FGF1 IRES used in this study is of cellular origin. This is 
the first time, to our knowledge, that a cellular IRES has been used 
in a vector expressing therapeutic molecules in a disease model. 
The FGF1 IRES has been chosen due to its efficiency in skeletal 
muscle and because its physiological properties are expected to 
be  closer  to  endogenous  genes  than  the  encephalomyocarditis 
virus IRES classically used in bicistronic vectors. Also, the FGF1 
IRES, at least in an adeno-associated virus vector context, allows 
optimal vector expression when compared to a similar vector with 
the  encephalomyocarditis  virus  IRES.10  Furthermore,  we  have 
previously shown that IRESs from angiogenic factor mRNAs, but 
not the encephalomyocarditis virus IRES, are activated in isch-
emic and hypoxic conditions.21,22 This has been confirmed in the 
present study. Such a controlled activation allowing a significant 
but limited expression of the transgenes may be a crucial feature 
of the FGF1 IRES containing vector.
The  main  mechanism  described  for  the  synergy  between 
FGF2 and Cyr61 is that Cyr61, having a high affinity with hepa-
ran sulfate proteoglycan, is able to specifically displace FGF2 from 
the extracellular matrix.15 Coexpression of low amounts of Cyr61 
could thus displace the endogenous FGF2 bound to the extracel-
lular matrix and also prevent sequestration of the FGF2 produced 
by the vector in the extracellular matrix, resulting in an efficient 
diffusion  of  FGF2  throughout  the  entire  limb.  Indeed,  larger 
amounts of diffusible FGF2 were detected in serum with the bicis-
tronic vector (data not shown). This could explain the increased 
distant arteriogenic effect of FGF2 in the thigh, when coexpressed 
with Cyr61. However, our data also indicate that Cyr61, especially 
when expressed in large amounts, shows intrinsic effects that are 
more likely related to its binding to specific receptors rather than 
to FGF2 displacement. Indeed, overexpression of Cyr61, but not 
FGF2, is able to accelerate the B16 melanoma tumor progression 
in mouse. This underlines the interest of using a vector generating 
low amounts of Cyr61, not only for its beneficial local synergistic 
effect with FGF2 but also to avoid systemic undesirable effects on 
tumor growth and potentially other actions such as aggravation of 
diabetic retinopathy.
We show that, in this given experimental model, the dose of 
bicistronic plasmid used (50 µg/mouse) elicits a very favorable 
benefit to risk ratio (i.e., therapeutic angiogenesis versus harm-
ful tumor growth). The absence of undesirable effects on tumor 
growth is reassuring in the perspective of clinical studies. However, 
dose–response should be established in a human clinical trial, 
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in particular because the profound histological alterations that 
  characterize the critical lower limb ischemia could alter transfec-
tion efficiency and vector expression.
These data provide important perspectives for gene therapy of 
lower limb ischemia. The FGF1 IRES–based vector constitutes an 
attractive tool to control both the long-term expression as well as 
establish a low dose and ratio of coexpressed angiogenic factors. 
Furthermore, this system offers the possibility to add a third, or 
even a fourth angiogenic factor to increase the synergy and obtain 
a functional vessel network with still lower doses of the angiogenic 
factors, thus diminishing again the risk of side effects and provid-
ing optimized angiogenic vector candidates for clinical trials of 
lower limb ischemia.
MAterIAls And Methods
Hindlimb ischemia mouse model. Animal experiments were conducted 
in accordance with recommendations of the European Convention for the 
Protection of Vertebrate Animals used for experimentation.
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Figure 7  Analysis of capillary density and mature vessel formation. (a) Representative photomicrographs of ischemic tibialis anterior muscles 
stained with antibodies against CD31, α-SMA, or β-dystroglycan, allowing the detection of capillaries, mature vessels, or muscle fibers, respectively, 
21 days after surgery and electrotransfer. Original magnification ×200. Bar = 67 µm. (b) Quantification of capillary density in ischemic tibialis ante-
rior muscle of treated (with pC-FGFiCyr, pC-Cyr, pC-FGF, or pC-FGFiL) or untreated (with pC-RiL) mice using anti-CD 31 antibody and reported 
to the number of muscle fibers. Data are expressed as the mean ± SEM (n = 6) (*P < 0.05, **P < 0.01 versus control group). (c) Quantification of 
mature vascular density in ischemic tibialis anterior muscle of treated (with pC-FGFiCyr, pC-Cyr, pC-FGF, or pC-FGFiL) or untreated (with pC-RiL) 
mice, using anti-α-SMA antibody and reported to the number of muscle fibers. Data are expressed as the mean ± SEM (n = 6) (**P < 0.01 versus 
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Experiments were performed on 12- to 15-week-old female C57BL/6 
ApoE−/− mice23 and on 4-week-old female C57BL/6 mice from Janvier 
(Le Genest St Isle, France).
Unilateral  hindlimb  ischemia  was  created  in  12-  to  15-week-old 
female C57BL/6 ApoE−/− mice as described.11 Animals were anesthetized 
and depilated using depilatory cream (Veet), and then an incision was 
performed in the skin overlying the middle portion of the right hindlimb. 
After ligation of the proximal end of the right femoral artery, the distal 
portion of the saphenous artery was ligated, and the artery and all branches 
from the inguinal ligament up to and including the saphenous–popliteal 
bifurcation were dissected free and excised.
For  hindlimb  ischemia  experiments,  12-  to  15-week-old  female 
ApoE−/− mice were randomly divided into six groups of six mice each. 
All mice underwent surgically induced hindlimb ischemia the same day 
as gene transfer. Mice underwent laser Doppler perfusion imaging before 
and after gene transfer, and 7, 14, and 21 days after gene delivery. Seven 
days after surgery and gene transfer, we evaluated the degree of ischemia 
by limb observation based on the presence or absence of pressure sores, 
gangrene, or autoamputation (clinical ischemia index). Twenty-one days 
after  surgery,  mice  underwent  angiography  and  then  tibialis  anterior 
muscles were harvested for immunohistological analysis after killing.
Laser Doppler perfusion imaging. Blood flow in both ischemic and nonis-
chemic hindlimbs was measured until day 21 using a PeriScan System 
blood perfusion monitor laser Doppler equipment (Laser Doppler perfu-
sion imaging system; Perimed, Stockholm, Sweden). Three consecutive 
measurements were averaged after scanning of the same region of interest 
(leg and foot) with the laser Doppler perfusion imaging. The perfusion sig-
nal was displayed in color codes ranging from dark blue (low or no perfu-
sion) to red (high perfusion). Results are expressed as the ratio of perfusion 
in the ischemic limb versus nonischemic hindlimb.
Angiography. Angiographic analysis of collateral vessel development in 
the ischemic limb was performed by angiography on anesthetized animals. 
After abdominal aorta exposure, a 24G polyethylene catheter (BD, Franklin 
Lakes, NJ) was used to cannulate the aorta, 5 ml phosphate-buffered saline 
was  injected,  followed  by  0.5–0.8 ml  contrast  medium  (Micropaque, 
  barium sulfate 1g/ml; Guerbet, Roissy, France).
High-definition angiograms were generated with a Faxitron X-Ray 
imager  (MX-20;  Faxitron  X-Ray,  Lincolnshire,  IL)  and  films  exposed 
10 seconds 22 kV, then numerized for quantitative evaluation using image 
analysis software Morpho Expert (Explora Nova, La Rochelle, France). 
Images  were  examined  to  identify  collateral  vessels  that  bridged  the 
ligated femoral artery. Morpho Expert allowed analysis of three criteria: 
angiographic score (vessel area), total length, and number of segments of 
collateral vessel network. These criteria were determined by pixel analysis 
and expressed as the ratio of the ischemic to nonischemic limb (R/L ratio). 
The area of interest was delineated by ligature position on the femoral 
artery, knee, edge of the femur, and leg external limit.
Histological analysis. Muscles were snap-frozen in isopentane cooled in 
liquid nitrogen and stored at −80 °C. Samples were embedded in OCT 
compound (Tissue-Tek; Sakura Finetek, Torrance, CA) and snap-frozen 
in  liquid  nitrogen.  A  series  of  8 µm  transverse  frozen-embedded  sec-
tions cut at 200 µm intervals over the muscle length were immunostained 
with specific antibodies. The capillaries were counted after staining with 
αCD31 antibody (rat monoclonal antibody against mouse CD31, 1:50; BD 
Biosciences Pharmingen, San Diego, CA). Macrophages were revealed with 
αCD11b antibody (rat monoclonal antibody against mouse CD11b, 1:20; 
ref. 550282; BD Biosciences Pharmingen). The avidin–biotin–horseradish 
peroxidase system (Vector Laboratories, Burlingame, CA) with diamin-
obenzidine as a chromogen (Dako, Glostrup, Denmark) was used to reveal 
immunoreactivity. Frozen sections were stained with monoclonal anti-
bodies against α-actin (α-SMA, 1:400, clone 1A4, Cy3 conjugate; Sigma-
Aldrich, St Louis, MO) and against human β-dystroglycan (Novocastra, 
Newcastle upon Tyne, UK), detected by biotinylated antibodies followed 
by  avidin-  fluorescein  isothiocyanate  (M.O.M.  kit,  Vector  Laboratories). 
Immunopositive signals were revealed using a fluorescein isothiocyanate–
conjugated  secondary  and  Cy3-conjugated  streptavidin,  and  examined 
under a fluorescent microscope (Nikon, Melville, NY) at ×200 magnifica-
tion. Capillaries, mature vessels, and fibers were automatically counted with 
Morpho Expert under a ×200 objective to determine the vascular density.
Tumor  transplantation  model.  Female  C57/BL6  mice,  4-week-old, 
were  divided  into  four  groups  (n  =  6):  a  pC-FGF-,  a  pC-Cyr-,  and  a 
  pC-FGFiCyr-treated group, and a control group. After anesthesia, vectors 
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Figure 8  effects of cyr 61 and FGF2 expressed via mono- and bicis-
tronic vectors on tumor growth. (a) B16F0 cells (250,000 cells) were 
transplanted subcutaneously in the right flank in C57Bl/6 mice divided 
into  four  groups  (n  =  6):  pC-RiL,  pC-FGF,  pC-Cyr,  and  pC-FGFiCyr 
(electrotransferred 7 days before B16F0 injections). Tumor growth was 
monitored three times a week 7 days after B16F0 cell implantation. 
Each point is the mean ± SEM of six mice per group. (**P < 0.01 ver-
sus control group). (b) Comparison of the average of subcutaneous 
tumors by weighing explanted tumors from mice in each group when 
the tumor burden in treated pC-Cyr mice required euthanasia. Data 
are the mean weights ± SEM from six mice per group. Experiments 
were performed in duplicate. (c) Quantification of capillary density in 
the nonischemic tibialis anterior muscles (left leg) of treated (pC-FG-
FiCyr, pC-Cyr, pC-FGF, or pC-FGFiL) or untreated (pC-RiL) mice using 
anti-CD 31 antibody and reported by µm2. Data are expressed as the 
mean ± SEM (n = 3).Molecular Therapy  vol. 17 no. 12 dec. 2009  2019
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(50 µg) were injected in tibialis anterior muscle followed by electrotransfer 
as described.8 Seven days later, mice were subjected to a subcutaneous injec-
tion of B16F0 cells in 100 µl phosphate-buffered saline in the right flank.
Tumor growth was monitored three times a week with a caliper 7 days 
after  B16F0  cell  implantation.  Tumor  volume  was  calculated  with  the 
formula: V = Dd² × 0.52, where V is volume, D is maximum tumor diameter, 
and d is diameter at 90 ° to D. When tumors reached a size >2,000 mm3, 
mice were euthanized, and tumors were excised and weighed.
Statistical  analysis.  All  statistical  determination  was  performed  with 
GraphPad Prism, version 4.0 (GraphPad, San Diego, CA). All data are pre-
sented as the mean ± SEM. One-way and two-way analysis of variance was 
used to evaluate the significance of differences between groups. In some 
cases, data were analyzed using the post hoc Student’s t-test for unpaired 
data  and  Bonferroni’s  correction  for  multiple  comparisons.  A  P  value 
of <0.05 was considered statistically significant.
suPPleMentAry MAterIAl
Figure S1.  Expression of mono- and bicistronic vectors in COS-7 cells.
Figure  S2.  Expression of Cyr61 and FGF2 proteins by mono- and 
  bicistronic vectors in tibialis anterior muscle.
Figure  S3.  Protein  and  RNA  expression  of  mono-  and  bicistronic 
  vectors in C2C12 myoblasts.
Figure S4.  Angiographic analysis of collateral vessel development in 
the ischemic limb treated by vector pC-FGFiCyr or pC-RiCyr.
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